A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
Clinical trial NCT00923247 · TERMINATED
Trial details
- NCT number
- NCT00923247
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-02-19
- Primary completion
- 2016-04-01
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.